Overview

Study to Assess the Efficacy and Safety of Ublituximab + Umbralisib With or Without Bendamustine and Umbralisib Alone in Patients With Previously Treated Non-Hodgkins Lymphoma

Status:
Active, not recruiting

Trial end date:
2025-07-01

Target enrollment:

Participant gender:

Summary

Unity NHL - A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + Umbralisib with or without Bendamustine and Umbralisib alone in Patients with Previously Treated Non-Hodgkin's Lymphoma

Phase:

Phase 2/Phase 3

Details

Lead Sponsor:

TG Therapeutics, Inc.

Treatments:

Bendamustine Hydrochloride